Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 6, 2015, Pages

  Kew, Kayleigh M ^a   Evans, David Jw ^b   Allison, Debbie E ^c   Boyter, Anne C ^c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL LANCASTER INFIRMARY   (United Kingdom)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID DERIVATIVE; FORMOTEROL; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; SALMETEROL XINAFOATE;

ADD ON THERAPY; ADULT DISEASE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; ASTHMA QUALITY OF LIFE QUESTIONNAIRE; CLINICAL EFFECTIVENESS; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; LUNG FUNCTION TEST; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ADULT; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; INHALATIONAL DRUG ADMINISTRATION; MALE; META ANALYSIS; MIDDLE AGED; PROCEDURES; QUALITY OF LIFE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ASTHMA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALMETEROL XINAFOATE; TIOTROPIUM BROMIDE;

EID: 84983096355     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011438.pub2     Document Type: Review

References (85)

1. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology 2011;128(2):315-22.
2. NCT00350207 A 16-week randomised, placebo-controlled, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat Inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16-Arg/Arg genotype. clinicaltrials.gov/show/NCT00350207 (accessed 18 December 2014).
3. Lane M. Tiotropium bromide in asthma patients: an alternative to inhaled long-acting beta-agonists?. Journal of the Royal College of Physicians of Edinburgh 2010;40(4):321-2.
4. NCT00565266 Asthma Clinical Research Network (ACRN) Trial - Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015).
5. Peters SP, Bleecker ER, Kunselman SJ, Icitovic N, Moore WC, Pascual R, et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology 2013;132(5):1068-74.
6. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. New England Journal of Medicine 2010;363(18):1715-26.
7. NCT00706446 Genotype stratified treatment with anticholinergic vs. beta-agonist (long acting) and exacerbations (GABLE). clinicaltrials.gov/show/NCT00706446 (accessed 18 December 2014).
8. NCT01172808 A phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 μg once daily) compared with placebo and salmeterol HFA MDI (50 μg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172808 (accessed 18 December 2014).
9. Casale T, Bleecker E, Meltzer E, Pizzichini E, Schmidt O, Bateman E, et al. Phase III trials to investigate tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy 2013;68:377.
10. Casale TB, Bateman ED, Dahl R, Pizzichini E, Vandewalker ML, Virchow JC, et al. Tiotropium Respimat (R) add-on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status. Journal of Allergy and Clinical Immunology 2014;133(2):Ab5.
11. NCT01172821 A phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 μg once daily) compared with placebo and salmeterol HFA MDI (50 μg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172821 (accessed 18 December 2014).
12. NCT01290874 Blacks and exacerbations on LABA vs. tiotropium (BELT). clinicaltrials.gov/show/NCT01290874 (accessed 18 December 2014).
13. Rajanandh MG, Nageswari AD, Ilango K. Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics 2014;36(4):526-33.
14. Ilango K. A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 8 January 2015).
15. Rajanandh MG, Nageswari AD, Ilango K. Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second-line treatment? A randomized trial. Clinical Therapeutics 2015;37(2):41826.
16. Rajanandh MG, Nageswari AD, Ilango K. Assessment of various second-line medications in addition to inhaled corticosteroid in asthma patients: a randomized trial. Clinical and Experimental Pharmacology and Physiology 2014;41(7):509-13.
17. Chest Research Foundation. A clinical trial comparing bronchodilator effects of two drugs, tiotropium bromide and formoterol fumarate each over 24 hours in subjects with asthma. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2008/091/000306 (accessed 8 January 2015).
18. Boehringer Ingelheim Pharma GmbH, Co. KG. The effect of tiotropium-bromide on deep inspiration-induced bronchodilation and airway responsiveness in asthma - tiotropium-bromide and lung mechanics. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-003385-34-NL (accessed 8 January 2015).
19. Saitama Medical University. Randomized clinical study with tiotropium and formoterol/budesonide in COPD with asthma. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000003618 (accessed 8 January 2015).
20. EACC (Ehime Asthma COPD Conference). Add-on therapy for COPD receiving inhaled bronchodilators. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000005459 (accessed 8 January 2015).
21. Fukuoka National Hospital. Study for effects of tiotropium on smokers and non-smokers with bronchial asthma. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010352 (accessed 8 January 2015).
22. Corren J, Frew A, Engel M, Schmidt H, Moroni-Zentgraf P, Kerstjens HAM. Tiotropium as add-on therapy to ICS+LABA in patients with symptomatic severe asthma: spirometric assessment over 24 hours [Abstract]. American College of Chest Physicians 2013;144(4):91A.
23. Kerstjens HAM, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. New England Journal of Medicine 2012;367(13):1198-207.
24. Vandewalker ML, Engel M, Schmidt H, Siebold W, Moroni-Zentgraf P, Kerstjens H, et al. Efficacy of tiotropium in patients with asthma in relation to allergic status [Abstract]. Journal of Allergy and Clinical Immunology 2013;131:AB1.
25. NCT00546234 Assessing treatment options for smokers with asthma. www.clinicaltrials.gov/ct2/show/NCT00546234 (accessed 8 January 2015).
26. National Jewish Health. Examining the link between obesity, inflammation, and response to asthma medications. clinicaltrials.gov/show/NCT00557180 (accessed 8 January 2015).
27. NCT00557700 Study to investigate the effect of inhaled tiotropium bromide on neurokinin-A induced bronchoconstriction in patients with mild-to-moderate asthma. www.clinicaltrials.gov/ct2/show/NCT00557700 (accessed 8 January 2015).
28. NCT00772538 A phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (5 mcg/day) over 48 weeks as add-on controller therapy on top of usual care in patients with severe persistent asthma. www.clinicaltrials.gov/ct2/show/NCT00772538 (accessed 8 January 2015).
29. NCT00776984 A phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (5 mcg/day) over 48 weeks as add-on controller therapy on top of usual care in patients with severe persistent asthma. www.clinicaltrials.gov/ct2/show/NCT00776984 (accessed 8 January 2015).
30. NCT01316380 A phase III, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 ug and 5 ug once daily) compared to placebo over 12 weeks in mild persistent asthma. www.clinicaltrials.gov/show/NCT01316380 (accessed 15 January 2015).
31. Paggiaro P, Engel M, Tudoric N, Forstner B, Radeczky E, Zubek V, et al. Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses [Abstract]. European Respiratory Journal 2013;42 (Suppl 57):877s.
32. Paggiaro P, Halpin DMG, Buhl R, Engel M, Zubek V, Blahova Z, et al. Tiotropium Respimat add-on to inhaled corticosteroids improves lung function in patients with symptomatic mild asthma: results from a phase III trial. Journal of Allergy and Clinical Immunology 2014;133(2):AB4.
33. NCT01340209 A phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 μg once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. www.clinicaltrials.gov/show/NCT01340209 (accessed 15 January 2015).
34. NCT01573624 Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). clinicaltrials.gov/show/NCT01573624 (accessed 18 December 2014).
35. NCT01641692 A multi-national, randomized, double-blind, placebo-controlled, 3-period crossover study with GSK 573719 as monotherapy in adult subjects with asthma. www.clinicaltrials.gov/ct2/show/NCT01641692 (accessed 8 January 2015).
36. NCT01696214 SAPS: Smoking Asthmatics Pilot Study. clinicaltrials.gov/show/NCT01696214 (accessed 18 December 2014).
37. NCT02066298 Steroids in eosinophil negative asthma. www.clinicaltrials.gov/ct2/show/NCT02066298 (accessed 8 January 2015).
38. NCT02127697 A randomized, double-blind, parallel group, 52-week study evaluating the efficacy, safety and tolerability of NVA237 in patients with poorly controlled asthma. www.clinicaltrials.gov/ct2/show/NCT02127697 (accessed 8 January 2015).
39. Vogelberg C, Engel M, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Downie J, et al. Once-daily tiotropium in adolescents with symptomatic asthma despite inhaled corticosteroid treatment: a dose-ranging study [Abstract]. Clinical and Translational Allergy 2014;4((Suppl 1)):2.
40. Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW. Beclomethasone versus placebo for chronic asthma. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD002738.pub2]
41. Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003135.pub4]
42. Allison DE, Kew KM, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS for adults with asthma. Cochrane Database of Systematic Reviews 2014, Issue 11. [DOI: 10.1002/14651858.CD011397]
43. Anderson HR. Prevalence of asthma. BMJ 2005;330:1037.
44. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. American Journal of Respiratory and Critical Care Medicine 2004;170(8):836-44.
45. Befekadu E, Onofrei C, Colice GL. Tiotropium in asthma: a systematic review. Journal of Asthma and Allergy 2014;7:11-21.
46. Joint Formulary Committee. British National Formulary. www.medicinescomplete.com (accessed 29 August 2014).
47. Brozek J, Oxman A, Schünemann H. GRADEPro Version 3.2 for Windows. McMasters, Canada, 2008.
48. British Thoracic Society/Scottish Intercollegiate Guidelines Network. BTS/SIGN British guideline on the management of asthma, October 2014. www.brit-thoracic.org.uk/guidelines-and-quality-standards/asthma-guideline/ (accessed 16 February 2015).
49. Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD007313.pub3]
50. Cates CJ, Wieland LS, Oleszczuk M, Kew KM. Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD010314.pub2]
51. Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD003137.pub5]
52. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD009157.pub2]
53. The Alfred Hospital, Monash University, National ICT Australia and the University of London. Covidence. 1. Melbourne: Alfred Health, 2013.
54. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 5. [DOI: 10.1002/14651858.CD005535.pub2]
55. Ducharme FM, Ni Choinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD005533.pub2]
56. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington H, Vale A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
57. Electronic Medicines Compendium. License extension 19th September 2014: Spiriva Respimat 2.5 micrograms solution for inhalation. www.medicines.org.uk/emc/history/20134 (accessed 24 October 2014).
58. Ernst P, McIvor A, Ducharme FM, Boulet LP, Fitzgerald M, Chapman KR, et al. Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. Annals of Internal Medicine 2006;146(9):692-4.
59. United States Food, Drug Administration. FDA Drug Safety Communication: New safety requirements for long-acting inhaled asthma medications called long-acting beta-agonists (LABAs). www.fda.gov/drugs/drugsafety/ (accessed 29 August 2014).
60. Global Initiative for Asthma. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. www.ginasthma.org/ (accessed 29 August 2014).
61. International Union Against Tuberculosis and Lung Disease. The Global Asthma Report 2011. theunion.org/what-we-do/publications/technical/global-asthma-report (accessed 1 September 2014).
62. Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respiratory Research 2006;7(1):73.
63. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
64. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009285.pub3]
65. Kew KM, Karner C, Mindus SM, Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2013, Issue 12. [DOI: 10.1002/14651858.CD009019.pub2]
66. Kew KM, Allison DE, Evans DJW, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD011437]
67. Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database of Systematic Reviews 2015, Issue 5. [DOI: 10.1002/14651858.CD011721]
68. Lipworth BJ. Emerging role of long acting muscarinic antagonists for asthma. British Journal of Clinical Pharmacology 2014;77(1):55-62.
69. MECIR Methodological Expectations for the conduct of Cochrane Intervention Reviews. editorial-unit.cochrane.org/mecir (accessed 3 February 2015).
70. Medicines and Healthcare Products Regulatory Agency (MHRA). Drug safety update: tiotropium. www.gov.uk/drug-safety-update/tiotropium (accessed 21 April 2015).
71. Medicines and Healthcare Products Regulatory Agency. Asthma long-acting ß2 agonists: use and safety. www.gov.uk/government/publications/asthma-long-acting-ss2-agonists-use-and-safety (accessed 16 February 2015).
72. Moulton BC, Fryer AD. Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD. British Journal of Clinical Pharmacology 2011;163(1):44-52.
73. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The salmeterol multicenter asthma research trial. Chest 2006;129:15-26.
74. Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD010509.pub2]
75. National Institute for Health and Care Excellence. NICE advice [KTT5] high-dose inhaled corticosteroids in asthma. www.nice.org.uk/Advice/ktt5 (accessed 1 September 2014).
76. Royal College of Physicians. Why asthma still kills: the national review of asthma deaths. www.rcplondon.ac.uk/sites/default/files/why-asthma-still-kills-full-report.pdf (accessed 1 September 2014).
77. Rashid Q, Klein R. Tiotropium in the treatment of patients with asthma. Southern Medical Journal 2014;107(5):330-7.
78. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
79. Rodrigo GJ, Castro-Rodríguez JA. What is the role of tiotropium in asthma? A systematic review with meta-analysis. Chest 2015;147(2):388-96.
80. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma related deaths. Annals of Internal Medicine 2006;144:904-12.
81. Tee A, Koh MS, Gibson PG, Lasserson TJ, Wilson A, Irving LB. Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD001281.pub2]
82. Tian JW, Chen JW, Chen R, Chen X. Tiotropium versus placebo for inadequately controlled asthma: a meta-analysis. Respiratory Care 2014;59(5):654-66.
83. Verhamme KM, Afonso A, Romio S, Stricker BC, Brusselle GG, Sturkenboom MC. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD. European Respiratory Journal 2013;42(3):606-15.
84. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, et al. Tiotropium Respimat Inhaler and the risk of death in COPD. New England Journal of Medicine 2013;369:1491-501.
85. Kew KM, Allison DE, Evans DJW, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD011438]